Immune checkpoint inhibitors targeting the interaction between PD1 and PDL1 are effective for immunotherapy in non-small cell lung cancer (NSCLC), which is the leading cause of cancer related death in the world. However, only subgroups of patients respond to therapy suggesting the existence of resistance mechanis...
S. Finotto, M. Chiriac, Susanne Krammer et al.· Journal of Immunology· 0 citations
A multi-population meta-analysis of genome-wide association studies, including 32,470 individuals with and 1,753,462 without bladder cancer, identifies 70 independent risk loci, of which 43 are novel, and uses experimental approaches to uncover how inherited variation influences this risk in the context of smoking.
L. Prokunina-Olsson, O. Flórez-Vargas, Michael G. Levin et al.· Nature Communications· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.